ATE345399T1 - Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten - Google Patents

Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten

Info

Publication number
ATE345399T1
ATE345399T1 AT99903188T AT99903188T ATE345399T1 AT E345399 T1 ATE345399 T1 AT E345399T1 AT 99903188 T AT99903188 T AT 99903188T AT 99903188 T AT99903188 T AT 99903188T AT E345399 T1 ATE345399 T1 AT E345399T1
Authority
AT
Austria
Prior art keywords
prostate cancer
treatment
methods
differentially expressed
biomarkers
Prior art date
Application number
AT99903188T
Other languages
English (en)
Inventor
Gang An
Robert W Veltri
Original Assignee
Dianon Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dianon Systems Inc filed Critical Dianon Systems Inc
Application granted granted Critical
Publication of ATE345399T1 publication Critical patent/ATE345399T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G01N2333/91085—Transglutaminases; Factor XIIIq (2.3.2.13)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99903188T 1998-01-21 1999-01-19 Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten ATE345399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/010,398 US5972615A (en) 1998-01-21 1998-01-21 Biomarkers and targets for diagnosis, prognosis and management of prostate disease

Publications (1)

Publication Number Publication Date
ATE345399T1 true ATE345399T1 (de) 2006-12-15

Family

ID=21745589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903188T ATE345399T1 (de) 1998-01-21 1999-01-19 Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten

Country Status (5)

Country Link
US (3) US5972615A (de)
AT (1) ATE345399T1 (de)
AU (1) AU746142B2 (de)
CA (3) CA2707152A1 (de)
DE (1) DE69933989T2 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535829D1 (de) 1994-08-20 2008-10-16 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US20020172953A1 (en) * 1996-07-29 2002-11-21 Mirkin Chad A. Movement of biomolecule-coated nanoparticles in an electric field
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) * 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
EP1818417B1 (de) 1996-07-29 2014-02-12 Nanosphere, Inc. Nanopartikel mit angehängten Oligonukleotiden und ihre Verwendungen
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6974669B2 (en) * 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US20050037397A1 (en) * 2001-03-28 2005-02-17 Nanosphere, Inc. Bio-barcode based detection of target analytes
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
ES2341926T3 (es) * 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
NZ506987A (en) 1998-03-17 2003-01-31 Sangamo Biosciences Inc Nucleic acid binding proteins
AU3463699A (en) * 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
EP1121198A1 (de) * 1998-10-14 2001-08-08 Arizona Board of Regents Immobilisiertes silberimmunoassaysystem
EP2000803A1 (de) 1998-11-30 2008-12-10 Nanosphere, Inc. Nanoteilchen mit Polymerschalen
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6703208B1 (en) 1999-10-20 2004-03-09 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
CA2387359A1 (en) * 1999-10-20 2001-04-26 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
CA2394850C (en) 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
EP1294930B1 (de) * 2000-01-13 2011-03-30 Nanosphere, Inc. Nanopartikel an denen oligonukleotide gebunden sind und deren verwendungen
CA2398155C (en) * 2000-01-24 2011-07-19 Sangamo Biosciences, Inc. Methods and compositions for linking binding domains in nucleic acid binding proteins
ATE324465T1 (de) * 2000-07-11 2006-05-15 Univ Northwestern Nachweismethode mittels verstärkter silberfärbung
JP2004511219A (ja) 2000-07-12 2004-04-15 アジェンシス，インコーポレイテッド 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
EP2316976A1 (de) * 2000-11-28 2011-05-04 Wyeth LLC Expressionsanalyse von FKBP Nukleinsäuren und Polypeptiden, die zur Diagnose und Behandlung von Prostatakrebs geeignet sind
MXPA03004579A (es) * 2000-11-28 2003-09-04 Wyeth Corp Analisis de expresion de acidos nucleicos del regulador de cromatina dependiente de actina y polipeptidos utiles en diagnostico y tratamiento del cancer de prostata.
US7037652B2 (en) * 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1425412A2 (de) * 2000-11-28 2004-06-09 University Of Cincinnati Beurteilung einer verletzung über das blut
WO2002046483A2 (en) 2000-12-06 2002-06-13 Northwestern University Silver stain removal from dna detection chips by cyanide etching or sonication
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
EP1341914A2 (de) * 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation der angiogenese durch zinkfinger-proteine
DK1353941T3 (da) * 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modificerede zinkfingerbindingsproteiner
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
WO2002068451A2 (en) * 2001-02-26 2002-09-06 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
US20060040286A1 (en) * 2001-03-28 2006-02-23 Nanosphere, Inc. Bio-barcode based detection of target analytes
AU2002254524A1 (en) * 2001-04-06 2002-10-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Use of semenogelin in the diagnosis, prognosis and treatment of cancer
FR2823092B1 (fr) * 2001-04-10 2004-03-05 Eurorad 2 6 Dispositif per-operatoire pour la localisation de tissus marques et procede utilisant un tel dispositif
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
US7147687B2 (en) * 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
WO2002096262A2 (en) * 2001-05-25 2002-12-05 Northwestern University Non-alloying core shell nanoparticles
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
WO2003016327A1 (en) * 2001-08-14 2003-02-27 Mount Sinai School Of Medicine Use of intrinsic reporters of cell signaling for high content durg profiling and toxicity screening
CA2466656C (en) * 2001-11-09 2013-07-02 Nanosphere, Inc. Bioconjugate-nanoparticle probes
CA2468408A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Human cdnas and proteins and uses thereof
US20040058857A1 (en) * 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
WO2003048769A1 (en) * 2001-11-30 2003-06-12 Nanosphere, Inc. Real-time monitoring of pcr amplification using nanoparticle probes
AU2002364202A1 (en) * 2001-12-21 2003-07-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Novel metastasis suppressor gene on human chromosome 8
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
WO2003075016A1 (en) * 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
US7280680B2 (en) * 2002-03-04 2007-10-09 Riken Method and apparatus for observing three-dimensional localizations of in vivo expressed genes as well as method and apparatus for observing minute three-dimensional localizations of in vivo expressed genes
US20030211488A1 (en) * 2002-05-07 2003-11-13 Northwestern University Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection
WO2004004647A2 (en) * 2002-07-02 2004-01-15 Nanosphere Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
AR044732A1 (es) * 2002-11-08 2005-10-05 H P B S A Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
WO2005001143A2 (en) * 2003-02-27 2005-01-06 Nanosphere, Inc. Label-free gene expression profiling with universal nanoparticle probes in microarray assay format
US20100022414A1 (en) * 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) * 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2006028601A2 (en) * 2004-07-26 2006-03-16 Nanosphere, Inc. Method for distinguishing methicillin resistant s. aureus from methicillin sensitive s. aureus in a mixed culture
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2007002567A2 (en) * 2005-06-23 2007-01-04 Nanosphere, Inc. Selective isolation and concentration of nucleic acids from complex samples
US20070029205A1 (en) * 2005-08-08 2007-02-08 Shoou-Aaey Chen Method of surface treatment for metal and nonmetal surfaces
JP2009505106A (ja) * 2005-08-19 2009-02-05 ナノスフェアー インコーポレイテッド Ｄｎａ及び抗体を含むハイブリッド基板を調製するための方法及びその使用
EP1984738A2 (de) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und kontrolle von nanoreaktoren
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP4190448A3 (de) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US9162039B2 (en) * 2006-08-18 2015-10-20 David M. Hoganson Flow directed guidewire
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
CA3170924A1 (en) * 2007-10-02 2009-04-09 Labrador Diagnostics Llc Modular point-of-care devices and uses thereof
AU2009258038A1 (en) * 2008-03-14 2009-12-17 Eastern Virginia Medical School Imaging mass spectrometry for improved prostate cancer diagnostics
EP3733871A1 (de) 2008-05-27 2020-11-04 Dako Denmark A/S Zusammensetzungen und verfahren zur erkennung von chromosomalen abweichungen mit neuen hybridisierungspuffern
ITRM20080310A1 (it) * 2008-06-12 2009-12-13 Ist Fisioterap Ospitalroma Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines.
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010096486A1 (en) * 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP2401396B1 (de) 2009-02-26 2016-11-23 Dako Denmark A/S Verfahren zur durchführung eines stringenten waschschritts bei hybridisierungsanwendungen
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
WO2010117768A1 (en) * 2009-04-10 2010-10-14 The Regents Of The University Of California Prostatitis-associated antigens and methods of use thereof
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP4435111A1 (de) 2010-02-12 2024-09-25 Bio-Rad Laboratories, Inc. Digitale analytanalyse
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012089772A2 (en) * 2010-12-30 2012-07-05 Febit Holding Gmbh Complex set of mirnas as non-invasive biomarkers for prostate diseases
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (de) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
EP2823303A4 (de) 2012-02-10 2015-09-30 Raindance Technologies Inc Molekulardiagnostischer screeningtest
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CN103674871B (zh) * 2012-09-19 2016-02-03 江南大学 一种综合判定啤酒酵母自溶情况的方法
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
RU2630648C2 (ru) * 2016-02-05 2017-09-11 Общество С Ограниченной Ответственностью "Биомаркер-Ру" Способ диагностики заболевания, сопровождающегося повышенной гибелью клеток, и набор для его осуществления
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3699594A1 (de) * 2019-02-22 2020-08-26 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verwendung von bmmf1-rep-protein als ein biomarker für prostatakrebs
AU2022240549A1 (en) * 2021-03-16 2023-10-05 Shanghai Biotroy Biotechnique Co., Ltd Semenogelin neutralizing antibody and epitope and application thereof
CN117487934B (zh) * 2023-12-20 2024-06-25 江苏金迪克生物技术股份有限公司 一种用于检测mdck细胞成瘤性相关基因的引物探针组合、试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2250993B (en) * 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
WO1993013207A2 (en) * 1991-12-31 1993-07-08 Zymogenetics, Inc. Novel human transglutaminases
DK0667920T3 (da) * 1992-10-29 2003-04-14 Univ Jefferson Fremgangsmåder til påvisning af prostatacancermetastase
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
CA2187775A1 (en) 1994-04-15 1995-10-26 Aaron E. Katz Method for molecular staging of prostate cancer
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1996021042A2 (en) 1995-01-04 1996-07-11 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences

Also Published As

Publication number Publication date
US20010007748A1 (en) 2001-07-12
AU746142B2 (en) 2002-04-18
US5972615A (en) 1999-10-26
CA2707152A1 (en) 1999-07-29
US6171796B1 (en) 2001-01-09
DE69933989T2 (de) 2007-07-05
DE69933989D1 (de) 2006-12-28
CA2318354A1 (en) 1999-07-29
CA2318354C (en) 2010-07-06
CA2707069A1 (en) 1999-07-29
AU2327099A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
ATE345399T1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
WO1997036535A3 (en) Biomarkers for detection, diagnosis and prognosis of prostate cancer
Aldouri et al. The risk of gallbladder cancer from polyps in a large multiethnic series
Yi et al. DNA methylation biomarker candidates for early detection of colon cancer
Fasching et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
ES2533428T3 (es) Uso de DPPIV/Seprasa como un marcador para el cáncer
Bettin et al. Gene Expression Profiling of Prostate Cancer–Associated Genes Identifies Fibromodulin as Potential Novel Biomarker for Prostate Cancer
WO2005100998A3 (de) Membrane markers for use in cancer diagnosis and therapie
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE329057T1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
Rapado-González et al. DNA methylation markers for oral cancer detection in non-and minimally invasive samples: a systematic review
Huang et al. Preliminary exploration of the clinical features of Chinese patients with skin malignancies and premalignancies: a retrospective study of 1420 cases from Peking University First Hospital
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
Barsola et al. Circulatory RNA based non-invasive detection and diagnosis of breast cancer
Sultanbaev et al. 25P Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Adiguzel et al. MMP-3 gene polymorphisms and Osteosarcoma
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
JP2007527241A5 (de)
Ting et al. 24P The Pink Vans: bringing cancer screening closer to home
EA200600012A1 (ru) Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties